The CDI Fast-MAb® antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native human proteins.
CDI utilizes its HuProt™ Human Proteome Microarray for validating the final product – therefore your antibody will be screened for cross-reactivity against ~75% of the human proteome.
Be Specific. Whether you are grant-writing, publishing or manufacturing... make CDI Fast-MAb part of your discovery and development success.
Fast-MAb monoclonal antibody development, production and purification, along with HuProt™ microarray validation, is an approximate 8 week process. It is a milestone-driven, 4-phase process with client reporting and assessment exchanged at each step. Invoicing begins at the initiation of Phase 1 and at the completion of each phase thereafter.
Milestones represent potential endpoints that depend on your project requirements or if the results-to-date fail to meet your expectations.
There is no charge for unsuccessful projects.
Antigen design, immunization strategy and screening methodology are critical to achieving high-value results.
CDI can fully-customize the development process to meet the requirements of the client and provide a quote based on deliverables.
5-mouse immunization regimen using 0.5-2 mg client-supplied protein of >80% purity or carrier-conjugated peptide.
Alternatively, CDI offers assistance in antigen design and synthesis.
Animals are boosted; test-bleeds subjected to ELISA titer and Ig class analysis. Client consultation.
2 top-responding animals are chosen, and immune cells are harvested for fusion with myeloma cells yielding multiple hybridomas.
Supernatants from IgG-secreting clones are screened by ELISA.
A minimum of 5 to a maximum of 30 high-quality clones are chosen and sub-cloned.
Each is expanded into 24-well plates and subsequently into T-25 flasks.
Supernatants are shipped for further client evaluation.
Each clone is vialed, labeled and frozen. Samples of each are reserved for mycoplasma testing.
Per client instructions, 3 select clones are placed into antibody production.
The resulting antibodies are purified and evaluated with CDI HuProt™ Human Proteome Microarray, v 3.1.
Detailed specificity data and additional QA documentation are prepared and shipped to the client along with the purified antibodies and all frozen clones.
For more information, including pricing, project initiation and additional antibody or microarray-related services, please call us at 787-806-4006.
Already have an antibody?
CDI offers HighSpec® cross-reactivity testing service using the
HuProt™ Human Proteome Microarray, v 3.1.
With the HuProt microarray, our expert scientists can help you eliminate false positive results from immunoassays and reduce potential off-target effects from therapeutics.
Click HERE for more information or please call us at 787-806-4006.